1H-吡咯并[3,2-B]吡啶-5-甲酸乙酯 | 1261433-14-0

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡咯并吡啶类
• 中文名称: 1H-吡咯并[3,2-B]吡啶-5-甲酸乙酯
• 英文名称: ethyl 1H-pyrrolo[3,2-b]pyridine-5-carboxylate
• CAS: 1261433-14-0
• 化学式: C₁₀H₁₀N₂O₂
• 分子量: 190.202
• InChiKey: DAMLMHAOXKDRKN-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.6
• 重原子数：
  14
• 可旋转键数：
  3
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.2
• 拓扑面积：
  55
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  1H-吡咯并[3,2-B]吡啶-5-甲酸乙酯 在 lithium aluminium tetrahydride 、 sodium hydride 作用下， 以 四氢呋喃 为溶剂， 反应 2.17h， 生成 (1-tosyl-1H-pyrrolo[3,2-b]pyridin-5-yl)methyl 4-methylbenzenesulfonate
  参考文献：
  名称：

  Design, Synthesis, and Pharmacological Evaluation of 5,6-Disubstituted Pyridin-2(1H)-one Derivatives as Phosphodiesterase 10A (PDE10A) Antagonists

  摘要：

  We report the design and synthesis of novel 5,6-diarylated pyridin-2(1H)-one derivatives as pharmacophoric PDE10A inhibitors. This highly potent molecular scaffold was developed from an inactive diarylpyridine-2-amine derivative 3b by extensive and systematic analogue synthesis and SAR analysis. Further optimization of the scaffold resulted in identification of pyridin-2(1H)-one 18b as a lead compound with good potency (IC50 = 1.6 nM) and selectivity (>6000-fold) over other related PDEs but with a poor pharmacokinetic profile. Careful metabolite profiling of 18b revealed that poor systemic exposure in rats (C-max = 44 ng/mL; AUC(0-t), = 359 ng.h/mL) at 10 mg/kg was due to the formation of O-glucuronide conjugate by phase 2 metabolism. The structure of the glucuronide metabolite was confirmed by retention time and LC-MS/MS fragmentation matching with the synthetic glucuronide 26. The problem of low exposure of 18b was effectively addressed by its conversion to an acetate prodrug 25b, which upon oral dosing resulted in an improved pharmacokinetic profile (C-max = 359 ng.h/mL; AUC(0-t), = 2436 ng.h/mL) and a desirable brain to plasma ratio of 1.2. The prodrug 25b showed good efficacy in selected rodent models of psychosis.

  DOI：

  10.1021/acs.jmedchem.5b01240
• 作为产物：
  描述：

  ethyl 5-amino-6-((trimethylsilyl)ethynyl)picolinate 在 吡啶 、 四丁基氟化铵 作用下， 以 四氢呋喃 、 二氯甲烷 为溶剂， 反应 10.0h， 生成 1H-吡咯并[3,2-B]吡啶-5-甲酸乙酯
  参考文献：
  名称：

  [EN] ARYL SUBSTITUTED OLEFINIC COMPOUNDS AS PDE10A INHIBITORS
  [FR] COMPOSÉS OLÉFINIQUES À SUBSTITUTION ARYLE EN TANT QU'INHIBITEURS DE LA PDE10A

  摘要：

  本发明提供了芳基取代烯烃化合物作为磷酸二酯酶1 0A（PDE 1 0A）抑制剂。具体来说，本文描述的化合物可用于通过抑制磷酸二酯酶1 0A酶来治疗或预防疾病、症状和/或紊乱。本文还提供了用于制备本文描述的化合物的工艺、用于合成的中间体以及它们的药物组合物。

  公开号：

  WO2011138657A1

文献信息

• [EN] ARYL SUBSTITUTED OLEFINIC COMPOUNDS AS PDE10A INHIBITORS<br/>[FR] COMPOSÉS OLÉFINIQUES À SUBSTITUTION ARYLE EN TANT QU'INHIBITEURS DE LA PDE10A
  申请人：GLENMARK PHARMACEUTICALS SA

  公开号：WO2011138657A1

  公开（公告）日：2011-11-10

  The present invention provides aryl substituted olefinic compounds as Phosphodiesterase 1 0A (PDE 1 0A) inhibitors. In particular, compounds described herein are useful for treating or preventing diseases, conditions and/or disorders by inhibiting Phosphodiesterase 1 0A enzyme. Also provided herein are processes for preparing compounds described herein, intermediates used in their synthesis, pharmaceutical compositions thereof.

  本发明提供了芳基取代烯烃化合物作为磷酸二酯酶1 0A（PDE 1 0A）抑制剂。具体来说，本文描述的化合物可用于通过抑制磷酸二酯酶1 0A酶来治疗或预防疾病、症状和/或紊乱。本文还提供了用于制备本文描述的化合物的工艺、用于合成的中间体以及它们的药物组合物。
• Design, Synthesis, and Pharmacological Evaluation of 5,6-Disubstituted Pyridin-2(1<i>H</i>)-one Derivatives as Phosphodiesterase 10A (PDE10A) Antagonists
  作者：V. S. Prasadarao Lingam、Dnyaneshwar H. Dahale、Vijay E. Rathi、Yogesh B. Shingote、Rajni R. Thakur、Ajit S. Mindhe、Srinivas Kummari、Neelima Khairatkar-Joshi、Malini Bajpai、Daisy M. Shah、Ratika S. Sapalya、Srinivas Gullapalli、Praveen K. Gupta、Girish S. Gudi、Satyawan B. Jadhav、Rambabu Pattem、Abraham Thomas

  DOI：10.1021/acs.jmedchem.5b01240

  日期：2015.10.22

  We report the design and synthesis of novel 5,6-diarylated pyridin-2(1H)-one derivatives as pharmacophoric PDE10A inhibitors. This highly potent molecular scaffold was developed from an inactive diarylpyridine-2-amine derivative 3b by extensive and systematic analogue synthesis and SAR analysis. Further optimization of the scaffold resulted in identification of pyridin-2(1H)-one 18b as a lead compound with good potency (IC50 = 1.6 nM) and selectivity (>6000-fold) over other related PDEs but with a poor pharmacokinetic profile. Careful metabolite profiling of 18b revealed that poor systemic exposure in rats (C-max = 44 ng/mL; AUC(0-t), = 359 ng.h/mL) at 10 mg/kg was due to the formation of O-glucuronide conjugate by phase 2 metabolism. The structure of the glucuronide metabolite was confirmed by retention time and LC-MS/MS fragmentation matching with the synthetic glucuronide 26. The problem of low exposure of 18b was effectively addressed by its conversion to an acetate prodrug 25b, which upon oral dosing resulted in an improved pharmacokinetic profile (C-max = 359 ng.h/mL; AUC(0-t), = 2436 ng.h/mL) and a desirable brain to plasma ratio of 1.2. The prodrug 25b showed good efficacy in selected rodent models of psychosis.